Summary
This 8-K filing reports on the results of Bristol Myers Squibb Company's (BMY) Annual Meeting of Stockholders held on May 5, 2015. The key takeaway for investors is the outcome of various shareholder votes on corporate governance and executive matters. Notably, all 11 director nominees were elected, and the appointment of Deloitte & Touche LLP as the independent auditor was ratified. The compensation of named executive officers received advisory approval. However, two significant management proposals aimed at amending the company's Certificate of Incorporation were rejected by shareholders. These included a proposal to designate the Delaware Chancery Court as the exclusive forum for certain legal actions and a proposal to remove supermajority provisions applicable to preferred stockholders. Additionally, a shareholder proposal regarding written consent actions was also rejected. These outcomes suggest a divergence in opinion between management and a portion of the shareholder base on certain governance issues.
Key Highlights
- 1All 11 director nominees were successfully elected to serve until the 2016 Annual Meeting.
- 2Shareholders approved the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2015.
- 3An advisory vote to approve the compensation of named executive officers received majority approval.
- 4A management proposal to make the Delaware Chancery Court the exclusive forum for certain legal actions was rejected.
- 5A management proposal to remove supermajority provisions for preferred stockholders was also rejected.
- 6A shareholder proposal concerning the ability to take action by written consent was rejected.